Ultragenyx Pharmaceutical Inc (RARE)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$34.80

Buy

$36.00

arrow-up$0.77 (+2.21%)

Prices updated at 17 May 2025, 00:08 EDT

Prices minimum 15 mins delay

Prices in USD

Ultragenyx Pharmaceutical Inc is biopharmaceutical company. It is engaged identification, acquisition, development and commercialization of novel products for treatment of rare & ultra-rare diseases, with a focus on debilitating genetic diseases.

NASDAQ

0.52%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Daniel G. Welch

CEO

Dr. Emil D. Kakkis, M.D.,PhD

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

1,294

Head office

60 Leveroni Court

Novato

United States

94949

+1 415 483-8800

dkeatley@ultragenyx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Deborah L. Dunsire,M.D. Independent Director	0.07m
Mr. Matthew K. Fust Independent Director	0.08m
Dr. Emil D. Kakkis, M.D.,PhD Director, President and Chief Executive Officer	0.86m
Mr. Daniel G. Welch Chairman of the Board	0.10m
Mr. Thomas R. Kassberg Chief Business Officer and Executive Vice President	-
Mr. Michael A. Narachi Independent Director	0.08m
Mr. Theodore A. Huizenga Senior Vice President, Corporate Controller and Chief Accounting Officer	-
Ms. Karah Parschauer Chief Legal Officer and Executive Vice President, Corporate Affairs	-
Mr. Dennis Karl Huang Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations	-
Mr. John Richard Pinion, II Chief Quality Officer and Executive Vice President, Translational Sciences	0.57m
Dr. Eric Crombez, M.D. Executive Vice President and Chief Medical Officer	0.59m
Dr. Shehnaaz Suliman, M.D. Independent Director	0.07m
Mr. Erik Harris Chief Commercial Officer and Executive Vice President	0.60m
Mr. Howard Horn Chief Financial Officer and Executive Vice President, Corporate Strategy	0.59m
Dr. Corazon Dating Sanders, PhD Independent Director	0.07m
Dr. Amrit Ray, M.D. Independent Director	0.06m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	9,996,226
BlackRock Inc	6,158,266
Sands Capital Management, LLC	4,163,561
Vanguard Investments Australia Ltd	2,829,703
Vanguard US Total Market Shares ETF	2,809,832

Director dealings

Date chevron-l-regular chevron-r-regular	Action
30 Dec 2024	-
10 Dec 2024	-
09 Dec 2024	-
10 Dec 2024	-
10 Oct 2024	-
16 Sep 2024	-
03 Sep 2024	-
03 Sep 2024	-
06 Aug 2024	-
02 Jul 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-
18 Jun 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.